These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24205696)

  • 1. [Assessment of anti-factor Xa activity for heparin and related products by chromogenic assays and thrombin generation tests].
    Suzuki A; Kaneko M; Kanno N; Yatomi Y
    Rinsho Byori; 2013 Jul; 61(7):567-75. PubMed ID: 24205696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
    Bauer KA
    J Thromb Haemost; 2011 Jul; 9 Suppl 1():12-9. PubMed ID: 21781237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
    Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
    J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.
    Turpie AG
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.